IDEAS home Printed from https://ideas.repec.org/a/nat/natcom/v13y2022i1d10.1038_s41467-022-33169-0.html
   My bibliography  Save this article

Effectiveness of an inactivated Covid-19 vaccine with homologous and heterologous boosters against Omicron in Brazil

Author

Listed:
  • Otavio T. Ranzani

    (Universitat Pompeu Fabra (UPF)
    Hospital das Clínicas, Faculdade de Medicina
    CIBER Epidemiología y Salud Pública (CIBERESP))

  • Matt D. T. Hitchings

    (University of Florida)

  • Rosana Leite Melo

    (Ministério da Saúde)

  • Giovanny V. A. França

    (Ministério da Saúde)

  • Cássia de Fátima R. Fernandes

    (Ministério da Saúde)

  • Margaret L. Lind

    (Yale School of Public Health)

  • Mario Sergio Scaramuzzini Torres

    (Municipal Health Secretary of Manaus)

  • Daniel Henrique Tsuha

    (Fundação Oswaldo Cruz)

  • Leticia C. S. David

    (Pan American Health Organization)

  • Rodrigo F. C. Said

    (Pan American Health Organization)

  • Maria Almiron

    (Pan American Health Organization)

  • Roberto D. Oliveira

    (State University of Mato Grosso do Sul)

  • Derek A. T. Cummings

    (University of Florida
    University of Florida)

  • Natalie E. Dean

    (Emory University)

  • Jason R. Andrews

    (Stanford University)

  • Albert I. Ko

    (Yale School of Public Health
    Fundação Oswaldo Cruz)

  • Julio Croda

    (Yale School of Public Health
    Fundação Oswaldo Cruz
    Universidade Federal de Mato Grosso do Sul)

Abstract

The effectiveness of inactivated vaccines (VE) against symptomatic and severe COVID-19 caused by omicron is unknown. We conducted a nationwide, test-negative, case-control study to estimate VE for homologous and heterologous (BNT162b2) booster doses in adults who received two doses of CoronaVac in Brazil in the Omicron context. Analyzing 1,386,544 matched-pairs, VE against symptomatic disease was 8.6% (95% CI, 5.6–11.5) and 56.8% (95% CI, 56.3–57.3) in the period 8–59 days after receiving a homologous and heterologous booster, respectively. During the same interval, VE against severe Covid-19 was 73.6% (95% CI, 63.9–80.7) and 86.0% (95% CI, 84.5–87.4) after receiving a homologous and heterologous booster, respectively. Waning against severe Covid-19 after 120 days was only observed after a homologous booster. Heterologous booster might be preferable to individuals with completed primary series inactivated vaccine.

Suggested Citation

  • Otavio T. Ranzani & Matt D. T. Hitchings & Rosana Leite Melo & Giovanny V. A. França & Cássia de Fátima R. Fernandes & Margaret L. Lind & Mario Sergio Scaramuzzini Torres & Daniel Henrique Tsuha & Let, 2022. "Effectiveness of an inactivated Covid-19 vaccine with homologous and heterologous boosters against Omicron in Brazil," Nature Communications, Nature, vol. 13(1), pages 1-10, December.
    • Handle: RePEc:nat:natcom:v:13:y:2022:i:1:d:10.1038_s41467-022-33169-0
    DOI: 10.1038/s41467-022-33169-0
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/s41467-022-33169-0
    File Function: Abstract
    Download Restriction: no
    File URL: https://libkey.io/10.1038/s41467-022-33169-0?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. Elie Dolgin, 2022. "Omicron thwarts some of the world’s most-used COVID vaccines," Nature, Nature, vol. 601(7893), pages 311-311, January.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Deborah Cromer & Megan Steain & Arnold Reynaldi & Timothy E. Schlub & Shanchita R. Khan & Sarah C. Sasson & Stephen J. Kent & David S. Khoury & Miles P. Davenport, 2023. "Predicting vaccine effectiveness against severe COVID-19 over time and against variants: a meta-analysis," Nature Communications, Nature, vol. 14(1), pages 1-9, December.
    2. Zhuoying Huang & Shuangfei Xu & Jiechen Liu & Linlin Wu & Jing Qiu & Nan Wang & Jia Ren & Zhi Li & Xiang Guo & Fangfang Tao & Jian Chen & Donglei Lu & Yuheng Wang & Juan Li & Xiaodong Sun & Weibing Wa, 2023. "Effectiveness of inactivated COVID-19 vaccines among older adults in Shanghai: retrospective cohort study," Nature Communications, Nature, vol. 14(1), pages 1-12, December.

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Suman Das & Janmejay Singh & Heena Shaman & Balwant Singh & Anbalagan Anantharaj & Patil Sharanabasava & Rajesh Pandey & Rakesh Lodha & Anil Kumar Pandey & Guruprasad R. Medigeshi, 2022. "Pre-existing antibody levels negatively correlate with antibody titers after a single dose of BBV152 vaccination," Nature Communications, Nature, vol. 13(1), pages 1-7, December.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:13:y:2022:i:1:d:10.1038_s41467-022-33169-0. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.